Medications for dyspnea depend almost entirely on what is causing the breathlessness, and no single drug reliably treats the sensation itself in all patients. When the underlying condition can be addressed directly, bronchodilators, diuretics, vasodilators, and corticosteroids often bring dramatic relief. When breathlessness persists despite treating its cause, the options narrow considerably, and the evidence behind them is thinner and more contested than many clinicians and patients expect.
Why the Cause Determines the Drug
Dyspnea is a symptom, not a disease, so the first medication you receive will almost always target the condition generating the breathlessness rather than the sensation itself. In obstructive lung diseases like COPD or asthma, inhaled bronchodilators are the backbone of treatment. Long-acting agents such as tiotropium and indacaterol open the airways and improve exercise tolerance. A crossover study found that both drugs individually improved lung function and the ability to exercise, and combining them pushed those gains further still.1PubMed Central. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
For COPD flare-ups, systemic corticosteroids reduce inflammation and speed recovery. A Cochrane review found that a shorter course of steroids worked about as well as a longer one, with no meaningful difference in treatment failure, relapse, or side effects.2PubMed Central. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease That is practical information for anyone dreading a long steroid taper: five days can accomplish what 14 days does, with fewer steroid-related problems along the way.
When the heart is the problem, the drugs change entirely. Heart failure causes fluid to back up into the lungs, making breathing feel heavy and labored. Intravenous diuretics like furosemide push excess fluid out through the kidneys, and vasodilators like nitroglycerin reduce the pressure overloading the heart. A case report and literature review highlighted how high-dose intravenous nitroglycerin reversed respiratory failure from hypertensive pulmonary edema within about 18 minutes, illustrating how aggressively targeting the cardiac cause can relieve breathlessness faster than treating the lungs themselves.3PubMed Central. Treatment of Hypertensive Cardiogenic Edema with Intravenous High-Dose Nitroglycerin in a Patient Presenting with Signs of Respiratory Failure: A Case Report and Review of the Literature
Opioids for Refractory Breathlessness
When the underlying disease has been treated as well as it can be and breathlessness still dominates someone’s life, clinicians often turn to low-dose opioids. The rationale makes intuitive sense: opioids dampen the brain’s respiratory drive and alter how the nervous system processes discomfort. They reduce breathing rate partly by acting on brainstem circuits that control the rhythm of breathing, and they also blunt the emotional distress that breathlessness provokes.4PubMed Central. Multi-Level Regulation of Opioid-Induced Respiratory Depression The unpleasantness of dyspnea activates the same brain regions involved in fear and emotional pain, particularly the anterior insula and amygdala, so an opioid’s ability to dull that circuit has biological plausibility.5American Journal of Respiratory and Critical Care Medicine. The Unpleasantness of Perceived Dyspnea Is Processed in the Anterior Insula and Amygdala
The clinical evidence, however, is weaker than many assume. A Cochrane review pooling data from multiple randomized trials found that opioids produced only a small improvement in breathlessness scores compared with placebo, while making participants roughly five times more likely to experience nausea, three times more likely to develop constipation, and nearly three times more likely to feel drowsy.6PubMed Central. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness Several well-designed individual trials have failed to find a meaningful benefit. The BEAMS trial gave 156 people with COPD either 8 mg or 16 mg of extended-release morphine daily, and after a week neither dose beat placebo on the main breathlessness score.7PubMed Central. Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease The BEAMS Randomized Clinical Trial A larger trial of nearly 300 participants found no difference between sustained-release morphine and placebo on the primary breathlessness measure either, though the placebo group actually used more rescue morphine doses, suggesting something psychological was at play.8Thorax. Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial
There are glimmers of benefit in secondary outcomes. An analysis from one of those same trials found that morphine improved overall health status, with a small but real gain in the ability to walk up stairs or hills, and a modest reduction in breathing rate.9JAMA Internal Medicine. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial This pattern, where opioids fall short on the headline breathlessness question but improve functional measures or quality of life, turns up repeatedly. It suggests the drugs may help people feel better in ways that a single “rate your breathlessness” scale does not capture well.
Safety Concerns with Low-Dose Morphine
One reason clinicians hesitate to prescribe opioids for breathlessness is the fear of dangerous respiratory depression. At the low doses used for dyspnea, that fear has not been borne out in daytime studies. But a randomized trial specifically looking at what happens overnight found that steady-state low-dose morphine lowered average and lowest oxygen levels during sleep, raised carbon dioxide levels by a few points, and roughly doubled the proportion of participants who met criteria for nighttime hypoventilation compared to placebo.10PubMed. The Effects of Low-Dose Morphine on Sleep and Breathlessness in COPD: A Randomized Trial Sleep quality itself did not change, and next-day alertness was unaffected, so the worry is not that patients feel worse, but that their breathing quietly deteriorates during sleep in a way they would not notice. For people with COPD already prone to low oxygen at night, this is not a trivial concern.
Benzodiazepines and Anxiety-Related Breathlessness
Because dyspnea and anxiety often feed each other in a vicious loop, benzodiazepines seem like a logical option. In practice, the evidence argues against them as standalone treatment. A Cochrane review of eight studies including over 200 participants found no benefit from benzodiazepines for relieving breathlessness in advanced cancer or COPD, and the drugs caused significantly more drowsiness than placebo.11PubMed Central. Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults A palliative care expert review reached the same conclusion: benzodiazepines alone do not help breathlessness, and they raise concerns about delirium and excessive sedation.12Journal of Pain and Symptom Management. Benzodiazepines in the Management of Dyspnea in Patients with Advanced Illness: Controversies in Palliative Care
The picture shifts when benzodiazepines are added to opioids rather than used alone. A study of hospitalized palliative care patients found that people receiving both a benzodiazepine and an opioid were roughly five and a half times more likely to report improved dyspnea than people receiving no medication, whereas opioids alone did not reach statistical significance.13Journal of Pain and Symptom Management. Management of Moderate-to-Severe Dyspnea in Hospitalized Patients Receiving Palliative Care That combination makes sense if you think about breathlessness as having both a physical and an emotional component: the opioid dials down the raw signal, and the benzodiazepine quiets the panic response layered on top. Current expert opinion reserves this combination for carefully selected patients with severe breathlessness and marked anxiety, particularly when life expectancy is limited.
Antidepressants Do Not Appear to Help
Selective serotonin reuptake inhibitors, especially sertraline, attracted interest because they reduce anxiety without the sedation and fall risk of benzodiazepines. An early case series of seven patients with obstructive airways disease reported subjective improvement in dyspnea when sertraline was added to their regimens.14PubMed. Sertraline effects on dyspnea in patients with obstructive airways disease But the only proper randomized trial found no difference between sertraline and placebo on any breathlessness measure over 28 days, even when looking specifically at participants with moderate or severe anxiety.15European Respiratory Journal. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial Sertraline may help mood or panic attacks on their own terms, but it does not appear to reduce breathlessness itself.
When Oxygen Helps and When It Does Not
You might assume that giving someone more oxygen would obviously ease breathlessness. It does, but only if the person’s blood oxygen is actually low. A meta-analysis of 18 trials in people with COPD who were not severely hypoxic found a statistically significant reduction in dyspnea with oxygen, though the effect was modest.16Cochrane Database of Systematic Reviews. Oxygen therapy for non-hypoxaemic chronic obstructive pulmonary disease In cancer patients with mild or normal oxygen levels, the picture was different: a meta-analysis found no improvement in dyspnea at all.17British Journal of Cancer. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis
A landmark trial tested oxygen versus room air delivered by nasal cannula in patients with life-limiting illness and refractory dyspnea. Both groups improved equally: morning breathlessness dropped by about a point on a ten-point scale regardless of whether patients received oxygen or plain air.18PubMed Central. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial The benefit came from airflow across the face, not from the oxygen itself. This is why clinicians sometimes recommend a handheld fan aimed at the cheeks: it stimulates the same facial nerve receptors that moving air from a cannula does, without the cost or hassle of an oxygen setup.
High-flow nasal cannula systems, which deliver warm, humidified air at up to 60 liters per minute, represent a separate category. These devices reduce the work of breathing through mechanical means, flushing out stale air from the upper airway and providing a small amount of positive pressure. Reviews have found they lower breathing rate and can reduce the need for more invasive ventilation.19PubMed. High-Flow Nasal Cannula Oxygen Therapy in Adults: Physiological Benefits, Indication, Clinical Benefits, and Adverse Effects Their role sits somewhere between a simple nasal cannula and a full ventilation mask, and they are increasingly used in acute care settings where breathlessness is severe.
Inhaled Furosemide and Other Experimental Approaches
One of the more intriguing experimental treatments is inhaled furosemide, the same diuretic commonly given intravenously for heart failure. When delivered as a mist into the lungs, furosemide appears to sensitize stretch receptors in the airways, essentially tricking the brain into thinking the lungs are inflating more than they actually are. Animal research confirmed that inhaled furosemide sensitizes slowly adapting stretch receptors while dampening the irritant receptors that trigger cough and discomfort.20American Journal of Respiratory and Critical Care Medicine. Responses of Tracheobronchial Receptors to Inhaled Furosemide in Anesthetized Rats A human experiment induced air hunger in healthy adults and found that inhaled furosemide relieved the “can’t get enough air” sensation specifically, without affecting the effort of breathing.21PubMed Central. Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial
This distinction matters because breathlessness is not one feeling. “Air hunger,” the panicky sense of suffocation, appears to involve different brain pathways than the “work” of breathing, which is more about chest muscle effort. A drug that relieves only one type might explain why some patients feel dramatically better and others shrug. Inhaled furosemide has not yet moved into mainstream clinical use, but it represents a promising line of research precisely because it targets a mechanism no current standard therapy addresses well.
Cannabis has also been explored, given its effects on mood and perception. A small pilot study found that people with COPD selected “air hunger” descriptors less often after receiving a cannabinoid compared to placebo, hinting at a subjective shift in how breathlessness felt, even though conventional breathlessness rating scales did not change.22PubMed. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety However, a subsequent randomized trial in adults with advanced COPD found that vaporized cannabis had no meaningful effect on exertional breathlessness, exercise endurance, lung function, or any measured physiological parameter.23Annals of the American Thoracic Society. Effect of Vaporized Cannabis on Exertional Breathlessness and Exercise Endurance in Advanced Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial The evidence here is thin, and what exists does not support cannabis as a dyspnea treatment.
How Route of Delivery Affects Response
For opioids specifically, how the drug reaches the body matters less than you might think. Nebulized morphine, which delivers the drug directly to the lungs, seemed like it should work better than injected morphine for a lung-related symptom. But a study in cancer patients found that nebulized and subcutaneous morphine reduced dyspnea by similar amounts, with breathlessness scores dropping from around 4-5 to 2-3 on a ten-point scale by either route.24PubMed. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study The study was small and could not rule out a real difference, but the results fit with the broader understanding that opioids relieve dyspnea mainly through central brain effects rather than by acting directly on lung tissue. If the benefit comes from changing how the brain processes the breathlessness signal, the route to the bloodstream matters less.
Managing Secretions and Breathing Sounds Near Death
In the last hours or days of life, a different kind of breathing difficulty emerges: the rattling sound caused by secretions pooling in the airway of a person too weak to cough or swallow. This “death rattle” is distressing primarily to family members and caregivers rather than the dying person, who is typically unconscious or semi-conscious. The medications used here are anticholinergic drugs, which dry up secretions.
The evidence supports starting these drugs preventively rather than waiting for the rattle to appear. Prophylactic scopolamine butylbromide roughly halved the proportion of patients who developed the rattle compared to placebo.25PubMed Central. Reducing death rattle at the end of life Once the rattle has begun, treatment is less clearly effective. A systematic review and network meta-analysis comparing several anticholinergics, including hyoscine hydrobromide, hyoscine butylbromide, atropine, and glycopyrrolate, found no statistically significant advantage for any of them over placebo for treating established death rattle, though hyoscine butylbromide ranked highest among the options.26PubMed. Effects of Anticholinergics on Death Rattle: A Systematic Review and Network Meta-Analysis An earlier evidence-based guideline noted that some response occurs in around 80 percent of treated patients and suggested that subcutaneous hyoscine hydrobromide was more effective at 30 minutes than glycopyrronium.27PubMed. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care The honest picture is messy: prevention works better than treatment, no one drug is clearly superior once secretions accumulate, and these medications are used as much for the comfort of the people watching as for the patient.
How Breathlessness Gets Measured in Research
One reason the medication evidence can feel contradictory is that breathlessness is notoriously hard to measure. It is entirely subjective, and different people experience it in different ways. Research trials typically ask patients to rate their breathing on a numerical scale from 0 to 10, or use a visual analog scale where you mark a point on a line. More comprehensive tools like the EXACT-Respiratory Symptoms instrument capture multiple dimensions including breathlessness, cough, sputum, and chest symptoms. Validation studies have shown that the breathlessness subscale of this tool correlates with how far someone can walk in six minutes and with how they rate their own disability.28PubMed Central. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials
But a single number cannot fully represent an experience that involves physical sensation, emotional distress, and functional limitation. A drug might reduce the panic of breathlessness without changing its intensity, or improve someone’s ability to climb stairs without shifting their rating on a 0-to-10 scale. This is likely part of why opioids sometimes improve health status and functional capacity while “failing” on the primary breathlessness score in the same trial. The field is slowly recognizing that better measurement tools, ones that distinguish air hunger from effort and capture the emotional dimension separately, might change which drugs appear to work and for whom. Until then, a negative result on a single breathlessness scale should not be read as proof that a patient’s experience did not improve at all.
Combining Medications with Non-Drug Strategies
In clinical practice, medications rarely work in isolation. Pulmonary rehabilitation programs that combine exercise training, breathing techniques, and psychological support consistently reduce dyspnea in people with chronic lung disease, and they create a foundation on which medications can work more effectively. A handheld fan directed at the face, as mentioned earlier, exploits the same airflow-sensing nerves that make nasal cannula air feel helpful. Positioning matters too: leaning forward with arms braced on a table or your knees gives the diaphragm more room to move. Clinical algorithms for managing refractory breathlessness in terminal care increasingly combine low-dose opioids with fan therapy and scheduled reassessment at 48-hour intervals, along with caregiver education to reduce the distress that watching someone struggle to breathe inevitably causes. The medications are one layer in a strategy that works best when it addresses the physical sensation, the emotional response, and the practical environment all at once.